Advance on diagnosis and prophylaxis of central nervous system involvement in non-Hodgkin lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 60-63, 2011.
Article
em Zh
| WPRIM
| ID: wpr-472035
Biblioteca responsável:
WPRO
ABSTRACT
Refractory central nervous system (CNS) lymphoma in patients with non-Hodgkin lymphoma (NHL) carries a poor prognosis, with a median survival of 2-6 months. CNS involvement in NHL is associated with young age, advanced stage, number of extranodal sites, elevated lactate dehydrogenase, and international prognostic index (IPI) score. The most promising treatment of autologous stem cell transplant can extend median survival from 10 to 26 months. CNS prophylaxis is required during the initial treatment of NHL subtypes that carry a high risk of CNS relapse, such as Burkitt lymphoma (BL), and lymphoblastic lymphoma.The use of CNS prophylaxis in the treatment of diffuse large B-cell lymphoma is controversial because of the low risk of CNS relapse (≈5 %) in this population. The risk models that aim to identify predictors of CNS relapse in NHL.
Texto completo:
1
Base de dados:
WPRIM
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2011
Tipo de documento:
Article